Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 5/20 | 0.69 |
| ▸ | TBXAS1 | P24557 | 7/20 | 0.68 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.60 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.56 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.54 |
| ▸ | MMP12 | P39900 | 1/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2385420 | 0.83 | LMNA (0.67) | FFAR1MKNK1MKNK2CYP2A6 | |
| SCHEMBL31338446 | 0.83 | LMNA (0.67) | FFAR1MKNK1MKNK2CYP2A6 | |
| SCHEMBL1211561 | 0.82 | FFAR1 (1.00) | FFAR1FFAR4MMP12KEAP1 | |
| SCHEMBL8618654 | 0.82 | FFAR1 (1.00) | FFAR1FFAR4MMP12KEAP1 | |
| SCHEMBL12646562 | 0.82 | HDAC1 (0.60) | TBXAS1MKNK1MKNK2HDAC1CYP2A6 | |
| SCHEMBL12251221 | 0.82 | MKNK1 (0.58) | TBXAS1MKNK1MKNK2CYP2A6MMP12 | |
| SCHEMBL6027 | 0.81 | MKNK1 (0.58) | TBXAS1MKNK1MKNK2CYP2A6 | |
| SCHEMBL29403620 | 0.81 | TBXAS1 (0.78) | FFAR1TBXAS1KEAP1 | |
| SCHEMBL333061 | 0.81 | TBXAS1 (0.78) | FFAR1TBXAS1KEAP1 | |
| SCHEMBL12646445 | 0.81 | FFAR1 (0.69) | FFAR1TBXAS1FFAR4MMP12KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293715-B2 | 10a-Azalide compound crosslinked at 10a- and 12-positions | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-10-23 | — | — | US | disclosed |
| US-20110237784-A1 | 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| US-20110152315-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | SYDDANSK UNIVERSITET | 2011-06-23 | — | — | US | disclosed |
| EP-2177526-A1 | 10A-AZALIDE COMPOUND CROSSLINKED AT POSITION-10A AND POSITION-12 | Taisho Pharmaceutical Co. Ltd. (JP) | 2010-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237784-A1 | 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS | DCLRE1A, AZI2, CHD9 | FFAR1 4348/4885TBXAS1 1880/4885MKNK1 3349/4885 |
| US-20110152315-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | GPR119, INSR, GPR65 | FFAR1 6/4885TBXAS1 738/4885MKNK1 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.